Natriuretic Peptides as Inclusion Criteria in Clinical Trials
نویسندگان
چکیده
منابع مشابه
Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort.
OBJECTIVE To identify the proportion of patients fulfilling the inclusion criteria widely used in most clinical trials for rheumatoid arthritis (RA)--including the recent clinical trials of anti-Tumor Necrosis Factor alpha (TNFalpha) agents--in a Turkish cohort. METHODS 186 consecutive RA patients attending a routine tertiary rheumatology clinic were evaluated in 2 groups: Early RA group (gro...
متن کاملNatriuretic peptides in clinical practice.
lutely no reason to choose one AT1receptor blocker over others. We believe, however, that it is of utmost importance to show efficacy in terms of prevention of target organ damage and mortality. This must not necessarily parallel the blood pressure lowering efficacy and should therefore be assessed for each AT1-receptor blocker in order to enable us as clinicians to establish the role of the re...
متن کاملInclusion of women in clinical trials
There is increasing concern among many in the medical arena about the extent to which the effects of treatment, either good or bad, apply to specific subgroups of individuals. Women comprise one of the most frequently considered 'subgroups' of patients. In the 1980s, much political attention was focused on concerns about equity in the research enterprise. In this paper, we briefly describe the ...
متن کاملCommentary Inclusion of women in clinical trials
There is increasing concern among many in the medical arena about the extent to which the effects of treatment, either good or bad, apply to specific subgroups of individuals. Women comprise one of the most frequently considered 'subgroups' of patients. In the 1980s, much political attention was focused on concerns about equity in the research enterprise. In this paper, we briefly describe the ...
متن کاملCan generic paediatric mortality scores calculated 4 hours after admission be used as inclusion criteria for clinical trials?
INTRODUCTION Two generic paediatric mortality scoring systems have been validated in the paediatric intensive care unit (PICU). Paediatric RISk of Mortality (PRISM) requires an observation period of 24 hours, and PRISM III measures severity at two time points (at 12 hours and 24 hours) after admission, which represents a limitation for clinical trials that require earlier inclusion. The Paediat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Heart Failure
سال: 2020
ISSN: 2213-1779
DOI: 10.1016/j.jchf.2019.12.010